Skye Bioscience, INC 8-K filings

Skye Bioscience and Redx Pharma announce a definitive agreement to merge, creating Fibrx Therapeutics, a fibrosis-focused company, backed by approximately $125 million in combined financings.

Skye Bioscience shareholders approved an amendment to increase authorized common stock from 100 million to 300 million shares.

Skye Bioscience faces potential delisting risk after falling below Nasdaq's $10 million minimum stockholders' equity requirement.

Skye Bioscience files an amendment to a previous 8-K report to correct a clerical error regarding the total number of shares underlying repriced stock options.

Skye Bioscience repriced all outstanding employee stock options to $0.6150 and appointed John P. Sharp as Chief Financial Officer.

Skye Bioscience, Inc. received a deficiency letter from Nasdaq for failing to maintain the minimum $1.00 bid price requirement, initiating a 180-day compliance period.

Skye Bioscience announced positive interim 52-week data from its Phase 2a extension study of nimacimab in combination with semaglutide, showing significant weight loss and reduced regain.

Skye Bioscience entered a non-exclusive collaboration and license agreement with Halozyme to develop a subcutaneous formulation of nimacimab using Halozyme's ENHANZE drug delivery technology.

Skye Bioscience reported its Q3 2025 financial results and positive topline data from its CBeyond Phase 2a study for nimacimab in obesity, highlighting significant weight loss and reduced rebound.

Skye Bioscience's nimacimab monotherapy failed its primary weight loss endpoint, but showed clinically meaningful additional weight loss in combination with semaglutide, with a favorable safety profile.

Skye Bioscience reported Q2 2025 financial results, highlighted progress in its Phase 2a obesity trial for nimacimab, and unveiled promising preclinical data suggesting superior weight loss durability and combination potential.

Skye Bioscience, Inc. reported a change in its independent registered public accounting firm from Marcum LLP to CBIZ CPAs P.C. and detailed the results of its 2025 Annual Meeting of Stockholders, including the re-election of directors and approval of executive compensation.

Skye Bioscience announced its Q1 2025 financial results and highlighted the progress of its lead drug candidate, nimacimab, in obesity treatment, showcasing promising preclinical data and ongoing clinical trial advancements.

Skye Bioscience announces completion of enrollment in its Phase 2a CBeyondTM trial for nimacimab, a CB1 inhibitor targeting obesity, and reports financial results for 2024, projecting cash runway through Q1 2027.

Skye Bioscience's Board of Directors approved an amended and restated inducement equity incentive plan, granting the administrator broader authority over equity awards in the event of a change in control.

Skye Bioscience announced its third quarter 2024 financial results, highlighted by the start of its Phase 2 obesity trial for nimacimab and positive preclinical data.

Skye Bioscience has increased the base salaries of its CEO and CFO, granted them stock options, and appointed a new Chairman of the Board.

Skye Bioscience stockholders approved an amended incentive plan, increasing share issuance and extending the plan's expiration date.

Skye Bioscience has appointed Puneet S. Arora, MD, as Chief Medical Officer, effective September 3, 2024, bringing extensive experience in clinical development and regulatory affairs.

Skye Bioscience has appointed Karen Smith to its Board of Directors, while also announcing the resignations of two existing board members, effective August 1, 2024.

Skye Bioscience discontinues its SBI-100 Ophthalmic Emulsion program after a Phase 2a trial failed to show a statistically significant improvement in intraocular pressure, redirecting resources to its obesity program.

Skye Bioscience has released an unaudited pro forma balance sheet demonstrating compliance with Nasdaq's minimum $5 million stockholders' equity requirement, following recent capital raises and a real estate sale.

Skye Bioscience has successfully completed a $40 million private placement with institutional investors to fund its clinical development and business activities.

Skye Bioscience has appointed Dr. Annalisa Jenkins to its Board of Directors, while also announcing the future resignation of Dr. Margaret Dalesandro.

Skye Bioscience's pro forma balance sheet, reflecting recent transactions including a private placement and real estate sale, shows stockholders' equity exceeding $5 million, meeting Nasdaq listing requirements.

Skye Bioscience has successfully raised $50.25 million through a private placement to fund its clinical trials for obesity and glaucoma treatments.